Mindset Pharma Inc. (“Mindset” or the “Company”) announced today that it has filed a number of provisional patent applications with the United States Patent and Trademark Office. These patent applications cover a comprehensive range of psychedelic compounds, and their related processing, potential compositions, and therapeutic uses.

Clinicians and regulators are rapidly forming a favorable consensus around using psychedelic medicines to treat neuropsychiatric disorders, and it is expected that the innovative compounds identified in the Mindset patent applications have significant potential to treat a wide array of such disorders. Furthermore, management believes that the Mindset compounds may represent an advancement in stability, efficacy, and safety over the “classic” psychedelics.

The compounds identified by Mindset include both derivatives of known psychedelics, which could be candidates for the expedited 505(b)2 approval pathway, as well as a class of novel psychedelics. The design of these compounds draw on years of medicinal chemistry and drug development by the Mindset scientific team.

Mindset has begun the pre-clinical work together with its research partners to select lead compounds and intends to accelerate this work, along with the filing of additional patent applications on other novel classes of psychedelics, in furtherance of its goal of building the world’s most valuable library of psychedelic intellectual property.

About Mindset Pharma

Mindset Pharma (“Mindset”) is a drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders.  Founded by serial entrepreneurs and domain experts in drug development and medicinal chemistry and based in Toronto, Canada, Mindset is assembling a proprietary library of transformative psychedelic intellectual property designed to address chronic neuropsychiatric disorders efficiently and safely.  

‍